MorphoSys Corp (MOR): Prakiraan rega marang bathi
The impeccable image of MorphoSys AG (MOR) was solidified following its acquisition by a Swiss behemoth, which confirmed the value of its antibodies. The company's forward P/E ratio demonstrates the market valuation dynamics of this quality, where 0.00 reflects the latest value of the metric. Market capitalization relies on the sale of lymphoma immunotherapies and licensing royalties. However, margins are constrained by staffing costs and patent litigation.
Rincian metrik lan analitis perusahaan MorphoSys Corporation (MOR)
- kuotasi lan prakiraan analis:
- data kapitalisasi bursa:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas MorphoSys AG|MOR - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas MorphoSys AG|MOR - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku MorphoSys Inc|MOR - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan MorphoSys|Rasio cepet morphosys.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
MOR - Bathi pungkasan|Bathi sing dikarepake MorphoSys AG|MOR - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep MorphoSys Corp|MOR - Kapitalisasi marang bathi resik kanthi nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan MorphoSys Inc|MOR - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan MorphoSys|MOR - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan morphosys.com|MOR - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep MorphoSys AG
Analisis kabeh metrik perusahaan:MOR MorphoSys
The valuation of MorphoSys AG (MOR) depends directly on the success of pelabresib and licensing payments, rendering future revenue highly volatile. By analyzing changes in the company's forward P/E ratio, an investor can assess the market consensus on earnings: extreme indicator values signal that the asset is overbought or undervalued, allowing for timely portfolio rebalancing to minimize the risk of deep drawdowns during a correction.
Pesaing langsung
Pangali Forward P/E ONC|Prakiraan rega marang bathi Halozyme Therapeutics, Inc. HALO|RevMed - Prakiraan rega marang bathi|Pangali Forward P/E Ascentage Pharma Corp AAPG|CGON - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi URGN (urogen.com)|BCAX: Pangali Forward P/E|Rasio prakiraan rega marang bathi Personalis Inc (PSNL)|Rega marang bathi mangsa ngarep Erasca Corp|Prakiraan rega marang bathi Delcath Corp (DCTH)|Rega marang bathi mangsa ngarep Y-mAbs Therapeutics (YMAB)|AURA - Rasio prakiraan rega marang bathi|Rega marang bathi mangsa ngarep Candel Therapeutics, Inc. CADL|Pangali mangsa ngarep rega marang bathi ARAY|SLS - Rega marang bathi mangsa ngarep|Rasio rega marang bathi sing dikarepake ACTU|CTOR: Pangali Forward P/E|TuHURA Biosciences - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Protara Therapeutics, Inc.|Rasio prakiraan rega marang bathi Fate Therapeutics Inc FATE|Rega marang bathi mangsa ngarep Aadi Bioscience Inc (WHWK)|Kapitalisasi marang proyeksi bathi tscan.com|Champions Oncology, Inc. - Prakiraan rega marang bathi|XBiotech Inc (XBIT) - Rasio prakiraan rega marang bathi|CVM - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi OS Therapies Inc. OSTX|RADX (Radiopharm Theranostics Limited) - Prakiraan rega marang bathi|Artiva Biotherapeutics - Pangali mangsa ngarep rega marang bathi|ANL (Adlai Nortye Ltd) - Pangali Forward P/E|Pangali Forward P/E verupharma.com|Pangali Forward P/E TPST|xiliotx.com (XLO) - Pangali forward rega marang bathi|Rega marang bathi mangsa ngarep Renovaro RENB|MURA - Prakiraan rega marang bathi|KAPA - Rega marang bathi mangsa ngarep|Rasio prakiraan rega marang bathi OnKure Therapeutics Inc|w2.cytomed.sg (GDTC) - Rega marang bathi mangsa ngarep|Curis - Pangali mangsa ngarep rega marang bathi|APLM (Apollomics Inc.) - Pangali Forward P/E|Prakiraan rega marang bathi Tharimmune Corporation (THAR)|Pangali Forward P/E ADVB|Pangali Forward P/E genprex.com (GNPX)|Rega marang bathi mangsa ngarep Calidi Biotherapeutics, Inc. CLDI|SBFM: Rasio rega marang bathi mangsa ngarep|Xenetic Bio - Pangali Forward P/E|Salarius Pharma (SLRX) - Prakiraan rega marang bathi|PPBT: Pangali Forward P/E|Rasio prakiraan rega marang bathi American Oncology Network, Inc. (AONC)|Rega marang bathi mangsa ngarep BeiGene|CKPT: Pangali mangsa ngarep rega marang bathi|Prakiraan rega marang bathi ELEV (Elevation Oncology, Inc.)|ICAD (icadmed.com) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E IKNA (Ikena Oncology)|NTBL - Prakiraan rega marang bathi|VIRX: Prakiraan rega marang bathi|NAYA - Pangali Forward P/E|Ascentage Pharma Group Ltd (AAPGV) - Rega marang bathi mangsa ngarep
